PLCB3 and colorectal carcinoma: Together, the results provide a promising perspective into PLCB3 and cetuximab in CRC, and underscore the potential of targeted therapy against PLCB3 and Wnt/β-catenin pathway in enhancing the efficacy of cetuximab-based CRC treatment.